1-Ethyl-2-methyl-1,2,3,4-tetrahydrochinolin | 21863-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-Ethyl-2-methyl-1,2,3,4-tetrahydrochinolin
• 英文别名: 1-Ethyl-1,2,3,4-tetrahydrochinaldin；1-ethyl-2-methyl-1,2,3,4-tetrahydroquinoline；1-Aethyl-2-methyl-1,2,3,4-tetrahydro-chinolin；1-ethyl-2-methyl-3,4-dihydro-2H-quinoline
• CAS: 21863-26-3
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: QNBYUEZFABKSFU-UHFFFAOYSA-N

物化性质

• 沸点：
  156-159 °C(Press: 22 Torr)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 tin 作用下， 生成 1-Ethyl-2-methyl-1,2,3,4-tetrahydrochinolin
  参考文献：
  名称：

  Moeller, Justus Liebigs Annalen der Chemie, 1887, vol. 242, p. 313

  摘要：

  DOI：

文献信息

• An efficient one pot transfer hydrogenation and N-alkylation of quinolines with alcohols mediated by Pd/C/Zn
  作者：Belén Abarca、Rosa Adam、Rafael Ballesteros

  DOI：10.1039/c1ob05888f

  日期：——

  A Pd/C/Zn mixture with alcohols has been revealed to be an efficient transfer hydrogenation system to quinolines. Furthermore, the metals mixture is able to activate alcohols as N-alkylating agents in a hydrogen autotransfer process. 1,2,3,4-Tetrahydroquinolines and N-alkylated tetrahydroquinolines from quinolines have been obtained with excellent yields in one step.

  一种Pd/C/Zn混合物与醇类一起被证明是一种有效的转移加氢体系，能够转化吡啶衍生物。此外，这种金属混合物能够将醇类激活为氮烷基化试剂，在氢的自转移过程中使用。由吡啶衍生物制备的1,2,3,4-四氢喹啉和N-烷基化四氢喹啉在一步反应中获得了优异的产率。
• [EN] INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2009050244A1

  公开（公告）日：2009-04-23

  The present invention provides compounds of formula (I), a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates, and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation and/or allergic conditions.

  本发明提供了化合物的结构式（I），其制备方法，包含该化合物的药物组合物及其制备，中间体，以及利用这些化合物制备药物治疗，特别是用于治疗炎症和/或过敏症状。
• Spirolactam Bicyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090325991A1

  公开（公告）日：2009-12-31

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS
  申请人：Shigeta Yukihiro

  公开号：US20100286390A1

  公开（公告）日：2010-11-11

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  化合物(I)是一种新型的吡啶并嗪酮化合物，可以抑制嘌呤能P2X7受体，因此可用于预防、治疗和改善炎症和免疫性疾病。
• Bicyclic Spirohydantoin CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090176757A1

  公开（公告）日：2009-07-09

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 and R 6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：(其中变量A1，A2，A3，A4，A5，A6，A7，B，E1，E2，E3，E4，E5，G1，G2和R6如本文所述)，它们是CGRP受体的拮抗剂，可用于治疗或预防CGRP参与的疾病，例如偏头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病中的使用。